key: cord-0854688-51ulu2pp authors: Mirzaei, Rasoul; Goodarzi, Pedram; Asadi, Muhammad; Soltani, Ayda; Aljanabi, Hussain ali abraham; Jeda, Ali Salimi; Dashtbin, Shirin; Jalalifar, Saba; Mohammadzadeh, Rokhsareh; Teimoori, Ali; Tari, Kamran; Salari, Mehdi; Ghiasvand, Sima; Kazemi, Sima; Yousefimashouf, Rasoul; Keyvani, Hossein; Karampoor, Sajad title: Bacterial co‐infections with SARS‐CoV‐2 date: 2020-08-08 journal: IUBMB Life DOI: 10.1002/iub.2356 sha: 5943063ea8bcf2295f7775e6d56cd1c66edda98a doc_id: 854688 cord_uid: 51ulu2pp The pandemic coronavirus disease 2019 (COVID‐19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), has affected millions of people worldwide. To date, there are no proven effective therapies for this virus. Efforts made to develop antiviral strategies for the treatment of COVID‐19 are underway. Respiratory viral infections, such as influenza, predispose patients to co‐infections and these lead to increased disease severity and mortality. Numerous types of antibiotics such as azithromycin have been employed for the prevention and treatment of bacterial co‐infection and secondary bacterial infections in patients with a viral respiratory infection (e.g., SARS‐CoV‐2). Although antibiotics do not directly affect SARS‐CoV‐2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co‐infection rather than virus itself. To date, a considerable number of bacterial strains have been resistant to various antibiotics such as azithromycin, and the overuse could render those or other antibiotics even less effective. Therefore, bacterial co‐infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID‐19. Also, the antibiotic‐resistant as a result of overusing must be considered. In this review, we will summarize the bacterial co‐infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID‐19. azithromycin, and the overuse could render those or other antibiotics even less effective. Therefore, bacterial co-infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID- 19 . Also, the antibiotic-resistant as a result of overusing must be considered. In this review, we will summarize the bacterial co-infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID-19. 19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first identified in December 2019 in Wuhan, China, and is currently circulating throughout the world. 1 By July 5, 2020, more than 11,125,245 million cases have been diagnosed in 216 countries, and more than 528,204 deaths have been reported. 2 The ongoing COVID-19 pandemic highlights the critical need for rapid development of vaccines and antiviral treatments to reduce the number of hospitalizations and deaths caused by this new dangerous coronavirus. 3 Co-infections and superinfections are common in respiratory viral infections. 4, 5 According to the laboratory, clinical, and epidemiological studies, secondary or bacterial co-infections with other viruses can significantly increase the mortality rate in patients infected with viral infections. 6, 7 It has previously documented that the mortality rate of viral infections can be influenced by different factors, such as bacterial co-infection. [8] [9] [10] For instance, influenza-related bacterial infections contribute to severe illness and mortality during the epidemic and seasonal influenza outbreaks. 11 Some influenzarelated bacterial species include Streptococcus pyogenes, Neisseria meningitidis, Moraxella catarrhalis, Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus. [11] [12] [13] [14] [15] [16] [17] [18] The mechanisms of severe complications caused by influenza-bacterial co-infections mainly include a lack of effective immune response as well as pathogenic synergy. 5 Although multiple microbial agents can cause acute lower respiratory tract infections, in most cases, the disease is caused by viruses and bacteria at the same time. 19 Secondary and bacterial co-infections with pandemics and viral epidemics have irreversible consequences, especially in high-risk groups, including those with immunodeficiency or immunosuppression. 20 Emerging evidence suggests that the number of patients with COVID-19 diagnosed with bacterial co-infections during hospitalization periods is increasingly raised. [21] [22] [23] The source and specific nature of these infections are yet to be fully explored, but there is some evidence suggesting that multidrug-resistant bacteria are among the pathogens that are thought to be responsible for the development of these infections. [21] [22] [23] Patients vulnerable to viral lung infections, such as influenza, severe acute respiratory syndrome (SARS), and COVID-19 are the greatest risk to be co-infected with superbugs. [21] [22] [23] [24] [25] For example, the 2009 H1N1 influenza pandemic caused approximately 300,000 deaths around the world in which 30-55% of cases die of bacterial pneumonia. 26, 27 It is now known that viral infections can weaken the host immunity, paving the way for the development of viral-bacterial co-infection. 28, 29 The new coronavirus, COVID-19, is another example of this fact as most of the hospitalized patients with COVID-19 acquired a secondary bacterial infection. [30] [31] [32] In some severe form of SARS-CoV-2, patients exhibited increased levels of infection-related biomarkers and inflammatory cytokines, suggesting potential bacterial co-infection as a result of the dysregulated immune system. 33 Besides, the emergence of antibiotic resistance could be an additional burden for the health care system as co-infection with coronavirus and pneumonia stretches health care units beyond their capabilities and resources. Understanding the mechanism underlying the synergy between Covid-19 and bacteria paves the way for the discovery of novel therapeutic agents to prevent the mortality rate in patients co-infected with COVID-19 and bacteria. In the current situation, appropriate and systematic analysis of COVID-19 patients diagnosed with bacterial co-infection should be implemented to choose proper antibiotics to increase the survival of patients and limit the spread of drug-resistant bacteria. The use of rapid diagnostic tools and methods promoting the prescription of effective narrow-spectrum antibiotics should be taken into account. In this review, we will summarize the current data available for bacterial infections in patients with COVID-19. Viral pneumonia and lower respiratory tract infections are well characterized in adult patients, including those diagnosed with severe forms of viral infection. 34 Most viral lower respiratory tract infections seem to be acquired in the community and considered a leading cause of infection in patients who undergo mechanical ventilation. 34 The most common cases diagnosed with bacterial co-infection with viral infections are seen in those infected with influenza virus. 27 The oldest report of bacterial infections that occurred simultaneously or shortly after influenza is related to the 1918 Influenza pandemic, in which most deaths occurred as a result of co-infection with infectious bacteria. 35 Also, the H1N1 Influenza pandemic in 2009 was complicated by bacterial pneumonia in 4-33% of hospitalized patients. [36] [37] [38] Bacterial-viral co-infection is not restricted to influenza and also caused by other respiratory viruses, such as parainfluenza virus, respiratory syncytial virus, adenovirus, rhinovirus, and human metapneumovirus. 34, 39, 40 Despite the discovery of antibiotics and viral vaccines in 1918-1957, the mortality rate, resulting from secondary bacterial pneumonia remained a major problem. The mortality rate seems to be still growing mostly because of the rapid rate of aging in the human population. 41, 42 Although viruses are commonly responsible for the development of acute upper and lower respiratory infections, in most cases patients may be infected by both bacterial and viral pathogens; however, the clinical manifestations at the early stages of the disease would not be nosologically distinguishable for physicians to differentially diagnose viral from a bacterial infection. 43 Recently, a group of respiratory emerging viruses has been identified, such as human coronavirus (HCoV), NL63, human bocavirus, influenza viruses' type H1N1 and H5N1, SARS, Middle East Respiratory Syndrome-related coronavirus (MERS), and Covid-19. [44] [45] [46] [47] [48] In children, atypical bacterial pathogens, such as Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae include the majority of infectious agents that cause mild, moderate, or even severe forms of acute respiratory infections. 49, 50 Bacterial co-infections with respiratory viral pathogens are very common, often through synergistic interaction among viruses such as influenza virus, and bacterial pathogens and the host immune system of the human being; nevertheless, the interaction between viruses and unusual bacteria is not yet fully understood. 50, 51 These secondary infections predominantly involve a specific group of bacterial pathogens, such as S. aureus, S. pneumoniae, S. pyogenes, and H. influenzae. [11] [12] [13] [14] [15] [16] [17] [18] A complete list of bacterial co-infections with viral pathogens is depicted in Table 1 . Commonly, viral infection can destroy histologically and functionally the respiratory tract of individuals upon viral spread. 42 Depending on the type of the virus, the histopathological outcomes could be relatively different from mild types to severe ones. These detrimental changes include altered mucus secretion, cell death, hyperplasia, decreased mucosal clearance, reduced oxygen exchange, and impaired surfactant secretion. 42, 77 Each of these effects is caused by various molecular mechanisms, depending on the virus, bacterial species, as well as the degree of the host immune reaction to either a bacterium or virus. 42 It has been noted that viral infections promote bacterial colonization of the airway through a variety of mechanisms. 42 Peltola and colleagues found that influenza viruses can enhance the colonization of the nasopharynx by S. pneumoniae bacterium, however, only particular subtypes were found to mediate the development of bacterial otitis media and sinusitis. 78 These data explain why the rate of bacterial infection is high in influenza seasons. 42 The neuraminidase enzyme of the influenza virus has been found to be presented on the host cell receptors, and they are employed for the adherence of bacteria due to its sialidase ability that changes the carbohydrate moieties on the host epithelial cells. 77, 79 This enzyme is also capable of increasing the possibility of bacterial adherence to the host cells through the stimulation of transforming growth factor-beta (TGF-β) which triggers the up-regulation of integrins and fibronectin. Integrins and fibronectin have been shown to act as receptors for bacteria. 80 Besides, interferons (IFNs) induction of by influenza virus can cause reduced C-C Motif Chemokine Ligand 2 (CCL2) expression resulting in failed macrophages recruitment that necessary for clearance of pneumococcal cells thereby enhance the colonization of S. pneumoniae in vivo. 81 Also, it has been found that the influenza virus predisposes the host to develop pneumonia caused by S. aureus where viral and bacterial loads are increased during co-infection. 52 It has been hypothesized that viral load is increased following bacterial coinfection because of increased shedding rate of the virus from infected host cells; however, bacterial loads would be elevated as a result of impaired function of alveolar macrophages. 82 Additionally, other upper respiratory tract viruses increase the adherence ability of bacterial pathogens to primary and immortalized epithelial cells with particular differences. Such differences are determined by the types of epithelial cells and their response to parainfluenza virus-3, respiratory syncytial virus, and/or influenza virus. 83 Novotny et al 84 showed that adenovirus and respiratory syncytial virus stimulated the expression of intercellular adhesion molecule 1 (ICAM-1) by primary respiratory tract epithelial cells. ICAM1 acts as a receptor for Type 4 pilus (T4P) of non-typeable H. influenzae (NTHI), thus promoting the binding of this pathogen to cells expressing this molecule. Also, respiratory syncytial virus infection increases the binding ability of P. aeruginosa to normal epithelial cells, as well as cells affected by cystic fibrosis. Such phenomena have been frequently employed by other bacteria to increase their virulence to infect the cells. 66 Studies have indicated that, following the infection with the respiratory syncytial virus, the rate of the binding of S. pneumoniae serotypes epithelial cells is increased by 2-10 folds. 85 Similarly, the antibody titers against S. pneumoniae are elevated in the nasopharynx when the cells co-infected with the respiratory syncytial virus, rhinovirus, and community-acquired pneumonia. 86 The higher degree of colonization of nasopharynx with S. pneumoniae is also found when the individuals are co-infected with viral upper respiratory tract infection or human immunodeficiency virus infection. 87 Bacterial and viral co-infection can alter some properties of the host mucosal immunity, leading to the failure in controlling the replication of bacteria in this site. 88, 89 Some key findings are discussed here, including the influence of viral infection on phagocytic activity. The reduction of alveolar macrophages by the influenza virus facilitates bacterial co-infection. 88, 90 Several lines of evidence demonstrated that 90% of resident alveolar macrophages were lost in the early weeks after influenza infection through tracking dye-labeled alveolar macrophages, 42 whereas 95% of the initial bacterial inoculum was eliminated during 3 hr by alveolar macrophages in non-influenza inoculated hosts. Notably, in those cells co-infected with influenza virus about 50% of the bacterial inoculum remained recoverable. 42 Also, it has been suggested that phagocyte activity, along with the cell proliferation could be influenced by viral infection. The infection of alveolar macrophages with influenza causes a marked decrease in the level of cytokines and chemokines, leading to decreased rates of recruitment and stimulation of neutrophils. 88 It may also suppress the phagocytic bacterial clearance mediated to nicotinamide adenine dinucleotide phosphate (NADPH), thereby increasing the susceptibility to secondary bacterial infection. 91 As mentioned earlier, the dysregulation of proinflammatory cytokine-induced by viral infection has been shown to play an essential role in the susceptibility of the cells to secondary bacterial infection. It is now known that type 1 IFNs have antiviral and immune-stimulatory properties and could have detrimental effects on human cells when their expression is inappropriate and excessive. It has been reported that IFNs play a fundamental role in the production of anti-inflammatory cytokines, such as interleukin (IL)-10 and IL-6, as well as the inhibition of proinflammatory cytokines, linking the innate immunity to adaptive immune responses, such as IL-17 and IL-23. They also decrease the activity of macrophages, dendritic cells, natural killer cells, along with the number of CD4-and CD8-positive T cells, leading to the impaired eradication of bacterial co-infection. 79, [92] [93] [94] Also, there are a number of mechanisms that are independent of the phagocytosis process by which viral host infection can predispose the human body to secondary bacterial co-infection. The production of antimicrobial peptides (AMPs), such as lipocalin-2, cathelicidin, Regenerating Islet Derived Protein 3 Beta (REG3B), calprotectin, may be dysregulated by upper respiratory tract viruses. 94 The respiratory syncytial virus infection is able to diminish the expression of human β-defensin-3 orthologue named chinchilla beta-defensin 1 when used in vivo. Of note, con-infection with the respiratory syncytial virus is capable of stimulating the viral load of Nontypeable Haemophilus influenzae (NTHi) in the nasopharynx by 10-100 folds. 95 The intranasal delivery of antichinchilla beta-defensin 1, human β-defensin 3, or the recombinant form of chinchilla beta-defensin 1 showed that the disruption of the availability of even a single innate immune effector could have a great impact on bacterial load since the viral infection has a critical in the loading of H. influenzae within the host airway. 95 Some mechanisms by which viral respiratory infections may predispose patients to bacterial infections to include failure immune response, viral-induced changes in epithelial cells, and the increased bacterial colonization 34 and summarize of the potential mechanisms responsible for bacterial coinfection with viral respiratory infections is depicted in Table 2 . The human immune reaction to SARS-CoV-2 infection is a two-step reaction that during the non-severe infection phase, a particular adaptive immune reaction is necessary to viral eradicate and prevent the disease from progressing to a severe phase. 127, 128 Hence, approaches to increase immune reactions such as using anti-serum and Pegylated IFNα are crucial at this phase. 127, 128 To provide a protective immune reaction in the early phase, the host must be in a good general health condition and have a genetic background to be able to exhibit an acceptable antiviral reaction. Genetic diversity is well known to involve in particular changes in the host immune response to various microbial pathogens. There is few information about the initial events in the process of virus elimination and inflammatory reactions during SARS-CoV infection. However, the innate immune reactions is mediated to the adaptive immunity development and disease severity in SARS-CoV. 129 Of note, SARS-CoV evolved escape mechanisms to avoid IFN responses in infected host cells. Besides, inflammatory reactions are regulated by inflammatory cytokines and chemokines such as IL-6, interferon-γ-inducible protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1) as well as the penetration of inflammatory cells such as macrophages into infected host tissues. 129 The suppression of antiviral type I interferons is one of the marked characteristics of SARS-CoV infection as well as other group II coronaviruses including mouse hepatitis virus. 130 It has been shown that the formation of type I interferons is impaired in host cells infected with SARS-CoV, but pretreatment of cells with IFN suppresses the growth of SARS-CoV. 131, 132 This shows that these viruses have developed mechanisms to overcome IFN responses in infected cells. Type I interferons are rarely found in acute SARS patients, and SARS-CoV is sensitive to Pegylated IFN-α, as shown in in vivo murine models. 133 Studies indicated that type I interferon suppression in SARS-CoV-infected hosts is mediated by the inactivation T A B L E 2 Summary of the potential mechanisms responsible for the bacterial coinfection with viral respiratory infections of the IRF-3 (interferon regulatory factor 3) protein, a transcriptional factor that controls the transcription of interferons. 132 Also, other SARS-CoV accessory proteins act as powerful interferon antagonists through various strategies. 129 For instance, N proteins inhibit the expression of interferons, whereas open-reading frame 3b and 6 proteins oppress the signaling pathway and expression of interferons. 129 Also, open-reading frame 6 proteins can halt the translocation of signal transducer and activator of transcription 1 (STAT1) . The open-reading frame 3b protein is a shuttling protein, impeding the stimulation of type I interferon, which is triggered by retinoic acidinducible gene 1 (RIG-I) and mitochondrial antiviralsignaling (MAVS) protein. 134 Additionally, M proteins suppress the production of type I interferon by inhibiting the generation of the TNF Receptor Associated Factor 3 (TRAF3)-TRAF Family Member Associated NFKB Activator (TANK) -TANK binding kinase 1 (TBK1)/IκB kinase ε (IKKε) complex. 134 Besides, SARS-CoV NSP1 proteins are able to halt the expression of IFN-β in host cells by promoting the degradation of the host mRNA and the suppression of the translation process. 135 A polyprotein complex of SARS-CoV named papain-like protease is able to inhibit the phosphorylation and nuclear translocation of IRF-3, resulting in disrupting the activation of type I IFN response via either Toll-like receptor 3 (TLR-3) or RIG-1/melanoma differentiation-associated gene 5 (MDA5) complex. 136 Also, infected cells with SARS-CoV can stimulate the expression of protein kinase R (PKR) and PKR-like endoplasmic reticulum kinase (PERK). 137 Although numerous studies performed on viral and bacterial co-infections, little information exists about human coronaviruses. In addition to seasonal influenza, it has been reported corona pathogens of pneumonia include coronavirus 229E, NL63, OC43, SARS, MERS, and SARS-CoV-2. These viruses can cause co-infection in the setting of community-acquired bacterial pneumonia. [138] [139] [140] [141] Human coronavirus NL63 (HCoV-NL63) has been recently discovered as a human respiratory pathogen with a high worldwide prevalence. 142, 143 Arguably, HCoV-NL63 is among the most clinically significant human coronaviruses and associated with upper and lower respiratory tract infections, frequently occurring in the winter and presenting more severe symptoms in children, the elderly, and immunocompromised patients. [142] [143] [144] In a study conducted by Golda et al., 143 they evaluated the impact of HCoV-NL63 on bacterial adherence causing respiratory tract diseases. HCoV-NL63 infection has been shown to enhance the adherence of S. pneumoniae to cells infected with the virus. 143 In one study, Zahariadis et al. 72 showed the coinfection of SARS patients with other pulmonary pathogens. They found that 30 and 9% of cases with SARS were co-infected with C. pneumoniae or M. pneumonia, respectively. Additionally, Alfaraj et al. 75 reported the coinfection of MERS-CoV with tuberculosis (TB) in two cases. In a study carried out by Wang et al., 145 they reported seven cases of SARS-related deaths who developed a secondary bacterial infection. The COVID-19 pandemic caused a large number of immunocompromised individuals to be hospitalized and some reports indicated that some COVID-19 patients were diagnosed with secondary infections. [30] [31] [32] The specific source and nature of these infections have not yet been fully investigated; however, there is evidence indicating that multidrug-resistant bacteria are among those microbes responsible for the development of these secondary infections. In one study, five cases (5.1%) with bacterial coinfections including Acinetobacter baumannii and Klebsiella pneumoniae were found among 99 patients, 146 while in another study, four cases (9.8%) with secondary bacterial infections were reported among 41 patients. 147 In a study performed by Zhang et al., 148 221 patients with SARS-CoV-2 pneumonia were admitted to Zhongnan Hospital, Wuhan, China. Among them, 25.8% (57/221) patients were afflicted with co-infections, and among these patients with co-infections, 29.8% (17/57) were co-infected with bacteria. In a study conducted by Blasco et al., 149 they detected one patient who was positive for M. pneumoniae coinfection among patients with COVID-19 pneumonia. Also, Claire et al. 150 reported a fatal case of necrotizing pneumonia induced by Panton-Valentine leukocidin-secreting S. aureus in a patient who was affected by COVID-19. Some patients infected with SARS-CoV-2 showed the increased levels of biomarkers and inflammatory cytokines related to co-infection by bacteria, caused by dysregulation in the immune system. 33 The management of the severe form of SARS-CoV-2 is similar to most viral pneumonia-causing respiratory failure. In a study carried out by Bordi et al., 151 they detected M. pneumoniae in five patients (4.0%), while only one patient was infected with L. pneumophila and S. pneumoniae (0.8%), and mixed infections were also observed in a small number of cases. They found the importance of using a broad-spectrum molecular diagnostic panel for rapid detection of the most common respiratory pathogens to improve evaluation and clinical management of patients with a respiratory syndrome consistent with COVID-19. 151 A list of bacterial coinfection with COVID-19 is depicted in Table 3 . One reason for this bacterial co-infection is due to many hospital-associated bacteria being adapted to develop an infection in individuals with a weakened immune system. It has been noted that the SARS-CoV-2 infection can damage the cells and the lung infrastructure. 160 Subsequently, the changed condition enables bacteria to increase adherence and invasion ( Figure 1 ). It has been found that the mortality rate of viral pandemics is heavily impacted by secondary bacterial infections with myriad numbers of people in the 1918 influenza pandemic as well as the 2009 pandemic, who died from secondary bacterial infections rather than the virus alone. 26, 27, 161 Despite the proven significance of co-infections in the severity of respiratory diseases, these kinds of infections during large outbreaks of respiratory infections are underdetermined. 162 For the precise diagnosis and evaluation of co-infections during the COVID-19 pandemic, samples must be taken longitudinally throughout the disease course via techniques independent of the culture for identifying mixed infections such as whole-genome metagenomics (WGMs). 162 Such works offer valuable monitoring findings on co-infection pathogens and drug-resistance infections resulting in improved antibiotic prescribing options. 162 Zhou et al. 163 found that in the current COVID-19 pandemic, 50% of patients who died from Covid-19 had bacterial co-infections. Correspondingly, Chen et al. 146 have reported fungal and bacterial co-infections in patients with COVID-19. COVID-19 patients are hospitalized on invasive mechanical ventilation for a long time, leading to higher chances of using a ventilator and hospital-acquired infections. 162 Thus, the rapid diagnosis of a broad range of potential pathogens and antimicrobial resistances for subsequent monitoring of co-infection would be crucial. The metagenome of COVID-19 patients has shown that Prevotella is a key player in immune response in a Chinese study, 156 while other opportunistic pathogens were found in a study conducted in the USA. [157] [158] [159] 164 There is a wide range of bacterial pathogens including Haemophilus, Lautropia, Prevotella have been detected as co-infection in Brazil, China, and the USA. [157] [158] [159] 164 However, a further concern with the rapid expansion of critical care capacity to manage SARS-CoV-2 can potentially increase the rate of nosocomial infection within the hospital environment. 165 To date, although the role of viral or bacterial co-infection in SARS-CoV-2 remains elusive, only a few SARS-CoV-2 patients worldwide have had documented evidence of co-infection; however, there is still a concern on this issue as many reports claim that a significant proportion of COVID-19 patients developed bacterial co-infections. It has been noted during the current pandemic, the antibiotic administration has been frequently used for COVID-19 patients who were admitted to the intensive care unit. 165 While scientists attempt to understand and control the COVID-19 pandemic, it would be also critical to prepare for the effect of the current and future viral pandemics on secondary bacterial infections, resulting in antimicrobial resistance in the near future. In combination with using an antimalarial drug, hydroxyl-chloroquine, azithromycin has become a popular therapeutic option for COVID-19 patients. Reports demonstrated that a combination of hydroxyl-chloroquine and azithromycin was effective for a large proportion of Covid-19 patients. 166, 167 It is hard to estimate how often this combination is prescribed, but such a rate would be high enough to cause a shortage of azithromycin. However, 30-40% of common types of bacterial agents are already resistant to azithromycin, and overuse could render this or other antibiotics even less effective. 168 The findings could help experts' advice on using the antibiotics in COVID-19 patients and help them to better understand the spread of co-infections in hospitals and the mechanism of bacterialviral coinfection. One factor that involves in the antibiotic resistance in bacterial co-infection is the widespread use of antibiotics in COVID-19 patients. Emerging data show that more than 90% of COVID-19 patients receive antibacterial drugs. 169, 170 This rapid increase in antibiotic administration can cause a strong selective pressure on bacterial pathogens to evolve resistance leading to the increased incidence of drug-resistant bacterial infections in the years subsequent to the COVID-19 pandemic. It was estimated that 10 million people could die from an antibiotic-resistant bacterial infection in the year of 2050, 171 but such prediction may be altered and shortened because of the devastating impact of the COVID-19 pandemic on the usage of antibiotics, so this timeline will almost have to be modified. Nevertheless, concerted efforts must be made to better understand antibiotic administration in COVID-19 patients. Antibiotics do not directly act on viral infections but viral respiratory infections often lead to bacterial co-infections. [30] [31] [32] The current pandemic highlights the necessity for understanding the complex relationship between viral and bacterial infections. Of note, in patients who have treated with highdose antibiotics may have more co-infections with drugresistant bacteria. Additionally, a recent clinical trial conducted by Hagan et al 172 demonstrated that the use of broad-spectrum antibiotics (which led to depleting gut microbiota) decreased and impaired the immune system's ability to generate antibodies. Also, the current study shows that the use of F I G U R E 1 Postulated schematic of bacterial coinfection with SARS-CoV-2 infection. It has been proposed when SARS-CoV-2 infects lung cells can damage the cells and the lung infrastructure. 160 This situation attracts neutrophil and macrophages to the site of infection and promoting the inflammation. 160 Finally, the changed situation and epithelial damage can cause bacteria to adhere to and invasion of the cells and proliferation. MQ, macrophage; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 antibiotics perturbed bile acid metabolism and induced inflammatory responses. 173 Hence, improved functional therapies, including antibiotics and alternative therapies as well as the prediction of bacterial respiratory infections using vaccines, should be regarded as potential therapeutic approaches. Besides, standard guidelines should also be established for the administration of the antibiotics. In addition to the direct effect on drug-resistant bacteria as a result of enhanced antibiotic administration, the transmission of drug-resistant bacteria through the medical system should be taken into account. The COVID-19 pandemic has highlighted the importance of vaccination, the need for functional antimicrobials, as well as the necessity for supporting research into the understanding and control of co-infections. Rapid characterization of co-infection is essential in the treatment of the most COVID-19 patients, and could help to save lives, and will improve antimicrobial stewardship during the pandemic. Additionally, mixed bacterial-viral infections can result in antibiotic treatment failure. These observations show that a better understanding of the underlying mechanisms will enable researchers to design effective preventive and therapeutic options. Several functional suggestions for management and control of bacterial co-infection with COVID-19 are offered in Table 4 . Respiratory viruses such as SARS-CoV-2 are wellcharacterized to cause severe disorders and pneumonia, particularly in individuals with serious medical comorbidities and aged populations. Additionally, respiratory virus infection could usually lead to enhanced susceptibility to secondary bacterial infections. However, the mechanisms responsible for bacterial-SARS-CoV-2 coinfection require further study. It has been noted that an elicited adaptive immune reaction toward viral infection fails the reaction of the host innate immunity against bacterial infection. This situation can explain why bacterial co-infections occur when the virus starts to be eradicated from the lungs of patients with COVID-19. This is accompanied by a shift in phagocytic activity of lung cells that mediate basal levels of innate protection via phagocytosis and pro-inflammatory cytokines formation to cells better attuned to antigen presentation and stimulation of adaptive immune reactions. Additionally, recently it has been found the microbiome diversity shapes our immune system. In line with this, the depletion of the gut microbiome hinders the immune system's ability to create a humoral response against viruses like the flu virus. However, this novel paradigm ultimately allows the development of new immune intervention approaches for the prevention and management of viral-bacterial co-infections in COVID-19 patients. The COVID-19 pandemic reinforces the importance of preventative measures such as vaccination and antimicrobial treatments in maintaining human health. Classifying mechanisms of pathogen interactions Increases the ability of infection control as the extension of chemotherapyresistant pathogens is a severe global obstacle 174 A novel coronavirus outbreak of global health concern Coronavirus disease (COVID-19) pandemic Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children When do coinfections matter? Mechanisms of bacterial superinfection post-influenza: A role for unconventional T cells How do viral infections predispose patients to bacterial infections? Immune dysfunction and bacterial coinfections following influenza Mechanisms of severe mortalityassociated bacterial co-infections following influenza virus infection The impact of virus infections on pneumonia mortality is complex in adults: A prospective multicentre observational study Impact of microbial Aetiology on mortality in severe community-acquired pneumonia Secondary bacterial infections in influenza virus infection pathogenesis Influenza complicated by Moraxella catarrhalis bacteremia The association of meningococcal disease with influenza in the United States Staphylococcus aureus and influenza A virus: Partners in coinfection Sepsis and pleural empyema caused by Streptococcus pyogenes after influenza a virus infection Direct interactions with influenza promote bacterial adherence during respiratory infections Severe community-acquired pneumonia due to Pseudomonas aeruginosa coinfection in an influenza a (H1N1) pdm09 patient Influenza and Staphylococcus aureus coinfection: TLR9 at play Chapter 93: Infections of the respiratory system Pandemics, public health emergencies and antimicrobial resistance -putting the threat in an epidemiologic and risk analysis context. Arch Public Health SARS-CoV-2, bacterial co-infections, and AMR: The deadly trio in COVID-19? Covid-19 induced superimposed bacterial infection Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing Why is coinfection with influenza virus and bacteria so difficult to control Nox2-derived oxidative stress results in inefficacy of antibiotics against post-influenza S. aureus pneumonia A tool for the potential fall 2009 wave of pandemic H1N1 to guide public health decision-making: An overview of the Public Health Agency of Canada's planning considerations Secondary bacterial infections associated with influenza pandemics Cooperation between viral and bacterial pathogens in causing human respiratory disease. Polymicrobial Diseases Virus-bacteria interactions: An emerging topic in human infection Coronavirus disease 2019 (COVID-19) and pregnancy: What obstetricians need to know Immunosuppression for hyperinflammation in COVID-19: A double-edged sword? Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection Epidemiology, coinfections, and outcomes of viral pneumonia in adults: An observational cohort study Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness Critical care services and 2009 H1N1 influenza in Australia and New Zealand Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia Critical illness from 2009 pandemic influenza a (H1N1) virus and bacterial coinfection in the United States Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae Influenza virus neuraminidase contributes to secondary bacterial pneumonia Complications of viral influenza Viral-bacterial co-infections in the respiratory tract The value of clinical features in differentiating between viral, pneumococcal and atypical bacterial pneumonia in children Cloning of a human parvovirus by molecular screening of respiratory tract samples The 2009 H1N1 influenza outbreak in its historical context Burden of disease due to human coronavirus NL63 infections and periodicity of infection Middle East respiratory syndrome coronavirus (MERS-CoV): Evidence and speculations From SARS to COVID-19: A previously unknown SARS-CoV-2 virus of pandemic potential infecting humans-call for a one health approach Atypical pneumonia Respiratory viruses and atypical bacteria co-infection in children with acute respiratory infection. Open Access Maced Insights into the interaction between influenza virus and pneumococcus Influenza virus primes mice for pneumonia from Staphylococcus aureus Importance of Staphylococcus aureus in pneumonia in the 1957, epidemic of influenza a Severe methicillin-resistant Staphylococcus aureus communityacquired pneumonia associated with influenza-Louisiana and Georgia Influenza-associated pediatric mortality in the United States: Increase of Staphylococcus aureus coinfection Infection with community-onset Staphylococcus aureus and influenza virus in hospitalized children Clinical findings in 111 cases of influenza a (H7N9) virus infection Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza Influenza and bacterial pathogen coinfections in the 20th century Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997) Moraxella catarrhalis pneumonia and bacteremia in an otherwise healthy child A simultaneous outbreak of meningococcal and influenza infections Invasive pneumococcal and meningococcal disease: Association with influenza virus and respiratory syncytial virus activity? Estimating the prevalence of coinfection with influenza virus and the atypical bacteria Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae Association of human metapneumovirus with radiologically diagnosed community-acquired alveolar pneumonia in young children RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma-possible synergism with Pseudomonas aeruginosa Mixed infection is common in children with respiratory adenovirus infection Bacterial involvement in parainfluenza virus infection in children The sialic acid binding activity of human parainfluenza virus 3 and mumps virus glycoproteins enhances the adherence of group B streptococci to HEp-2 cells Incidence of human rhinovirus coinfection with Staphylococcus aureus among HIV patients suffering from flu like illness Risk of ruling out severe acute respiratory syndrome by ruling in another diagnosis: Variable incidence of atypical bacteria coinfection based on diagnostic assays Increase in methicillinresistant Staphylococcus aureus acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome Outbreak of methicillinresistant Staphylococcus aureus infection associated with an outbreak of severe acute respiratory syndrome Middle East respiratory syndrome coronavirus and pulmonary tuberculosis coinfection: Implications for infection control. Intervirology Macrolides in critically ill patients with Middle East respiratory syndrome The co-pathogenesis of influenza viruses with bacteria in the lung Bacterial sinusitis and otitis media following influenza virus infection in ferrets Postinfluenza bacterial pneumonia: Host defenses gone awry Influenza viral neuraminidase primes bacterial coinfection through TGF-β-mediated expression of host cell receptors Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice Kinetics of coinfection with influenza a virus and Streptococcus pneumoniae Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species-and cell typedependent manner Intercellular adhesion molecule 1 serves as a primary cognate receptor for the type IV pilus of nontypeable Haemophilus influenzae Enhanced adherence of Streptococcus pneumoniae to human epithelial cells infected with respiratory syncytial virus Pneumococcal bacterial load colonization as a marker of mixed infection in children with alveolar community-acquired pneumonia and respiratory syncytial virus or rhinovirus infection High nasopharyngeal pneumococcal density, increased by viral coinfection, is associated with invasive pneumococcal pneumonia Regulating the adaptive immune response to respiratory virus infection Co-infection subverts mucosal immunity in the upper respiratory tract Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant Staphylococcus aureus infection Disease-promoting effects of type I interferons in viral, bacterial, and coinfections The role of virus infection in deregulating the cytokine response to secondary bacterial infection The immunology of influenza virus-associated bacterial pneumonia Respiratory syncytial virus-induced dysregulation of expression of a mucosal β-defensin augments colonization of the upper airway by non-typeable Haemophilus influenzae Bacterial adherence to virus-infected cells: A cell culture model of bacterial superinfection Adherence of Pseudomonas aeruginosa to tracheal cells injured by influenza infection or by endotracheal intubation Possible mechanisms of viral-bacterial interaction in swine Viral-bacterial synergistic interaction in respiratory disease Effect of swine fever live vaccine on the mucociliary apparatus of swine, and its interaction with Pasteurella multocida Effect of virus infection on the inflammatory response. Depression of macrophage accumulation in influenza-infected mice Alterations in lung macrophage immune receptor (s) activity associated with viral pneumonia Alterations in lung macrophage antimicrobial activity associated with viral pneumonia Immature circulating neutrophils in sepsis have impaired phagocytosis and calcium signaling Neutrophils in community-acquired pneumonia: Parallels in dysfunction at the extremes of age Diesel exhaust enhanced susceptibility to influenza infection is associated with decreased surfactant protein expression Decreased expression of surfactant protein D mRNA in human lungs in fatal cases of H5N1 avian influenza Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia Role of autophagy and apoptosis in the Postinfluenza bacterial pneumonia Interferon-inducible antiviral effectors Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice Influenza a virus exacerbates Staphylococcus aureus pneumonia in mice by attenuating antimicrobial peptide production Influenza-induced type I interferon enhances susceptibility to gram-negative and grampositive bacterial pneumonia in mice Influenza and bacterial superinfection: Illuminating the immunologic mechanisms of disease Compromised defenses: Exploitation of epithelial responses during viral-bacterial co-infection of the respiratory tract Influenza promotes pneumococcal growth during coinfection by providing host sialylated substrates as a nutrient source Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity Nutritional immunity: Starving pathogens of trace minerals Tuberculosis and HIV co-infection Epidemiology of human immunodeficiency virusassociated pulmonary disease Molecular diagnosis of TB in the HIV positive population Role of Staphylococcus protease in the development of influenza pneumonia A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza a viruses contributes to increased virulence Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells Dynamic changes in the Streptococcus pneumoniae transcriptome during transition from biofilm formation to invasive disease upon influenza a virus infection Streptococcus pneumoniae biofilm formation and dispersion during colonization and disease SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment SARS-CoV-2 and COVID-19 in older adults: What we may expect regarding pathogenesis, immune responses, and outcomes Host immune responses to SARS coronavirus in humans Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation. Microbiology and molecular biology reviews: MMBR 72 Treatment of SARS with human interferons Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3 Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity Viral and atypical bacterial detection in acute respiratory infection in children under five years Viral-bacterial co-infection in Australian indigenous children with acute otitis media Clinical impact of combined viral and bacterial infection in patients with communityacquired pneumonia First COVID-19 infections in the Philippines: A case report Human coronavirus NL63 associated with lower respiratory tract symptoms in early life Infection with human coronavirus NL63 enhances streptococcal adherence to epithelial cells Human coronavirus NL63 and 229E seroconversion in children Organism distribution and drug resistance in 7 cases of severe acute respiratory syndrome death patients with secondary bacteria infection Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical features and outcomes of 221 patients with COVID-19 in Wuhan Co-detection of respiratory pathogens in patients hospitalized with coronavirus viral disease-2019 pneumonia Panton-valentine Leukocidin-secreting Staphylococcus aureus pneumonia complicating COVID-19 Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2) Panton-valentine Leukocidin-secreting Staphylococcus aureus pneumonia complicating COVID-19 COVID-19 and Mycoplasma pneumoniae coinfection Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: A retrospective, single-Centre, descriptive study Clinical features of 69 cases with coronavirus disease Metagenome of SARS-Cov2 patients in Shenzhen with travel to Wuhan shows a wide range of species-Lautropia, Cutibacterium, Haemophilus being most abundant-and Campylobacter explaining diarrhea Wuhan outbreak could be caused by the bacteria Prevotella, which is aided by the coronavirus, possibly to adhere to epithelial cells-Prevotella is present in huge amounts in patients from both China and Hong Kong San Diego county Nanopore SARS-Cov2 sequencing data shows metagenomic Prevotella, Haemophilus parainfluenzae, a lot of unknown species and chimeric reads Metagenome of SARS-Cov2 from a patient in Brazil shows a wide range of bacterial species-Lautropia, Prevotella, Haemophilus-overshadowing viral reads, which does not even add up to a full genome The trinity of COVID-19: Immunity, inflammation and intervention The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09 Co-infections: Potentially lethal and unexplored in COVID-19 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. bioRxiv Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an openlabel non-randomized clinical trial Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases Teicoplanin: An alternative drug for the treatment of coronavirus COVID-19 Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study The drug-resistant bacteria that pose the greatest health threats Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans Antibiotics blunt flu immunity The potential impact of coinfection on antimicrobial chemotherapy and drug resistance Biofilm infections, their resilience to therapy and innovative treatment strategies Bacterial co-infections with SARS-CoV-2. IUBMB Life. 2020;1-15 The authors declare no conflicts of interest.